Skip to main content
Journal cover image

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780

Publication ,  Journal Article
Savarese, D; Taplin, ME; Halabi, S; Hars, V; Kreis, W; Vogelzang, N
Published in: SEMINARS IN ONCOLOGY
October 1, 1999

Duke Scholars

Published In

SEMINARS IN ONCOLOGY

ISSN

0093-7754

Publication Date

October 1, 1999

Volume

26

Issue

5

Start / End Page

39 / 44

Publisher

W B SAUNDERS CO

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Savarese, D., M. E. Taplin, S. Halabi, V. Hars, W. Kreis, and N. Vogelzang. “A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.” SEMINARS IN ONCOLOGY 26, no. 5 (October 1, 1999): 39–44.
Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780. SEMINARS IN ONCOLOGY. W B SAUNDERS CO; 1999 Oct 1;26(5):39–44.
Journal cover image

Published In

SEMINARS IN ONCOLOGY

ISSN

0093-7754

Publication Date

October 1, 1999

Volume

26

Issue

5

Start / End Page

39 / 44

Publisher

W B SAUNDERS CO

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis